Ocular Manifestations of Pediatric Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis by Ottaviano, Giorgio et al.
Ac
ce
pte
d M
an
us
cri
pt
Manuscript Doi: 10.1093/ecco-jcc/jjy029 
Copyright © 2018 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford 
University Press. All rights reserved. For permissions, please email: 
journals.permissions@oup.com 
OCULAR MANIFESTATIONS OF PEDIATRIC INFLAMMATORY BOWEL DISEASE:  
A SYSTEMATIC REVIEW AND META-ANALYSIS 
 
Giorgio Ottaviano
1
, Silvia Salvatore
1
, Alessandro Salvatoni
1
, Stefano Martelossi
2
, Alessandro 
Ventura,
2,3
 Samuele Naviglio
2,3 
 
1. Pediatric Department, Ospedale “F. Del Ponte”, Università dell’Insubria, Varese, Italy 
2. Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy  
3. Department of Medicine, Surgery, and Health Sciences, University of Trieste, Trieste, 
Italy 
 
Corresponding author:  Samuele Naviglio, MD 
Department of Medicine, Surgery, and Health Sciences, University of Trieste 
Via dell’Istria 65/1, 34137, Trieste, Italy 
Phone: +393382883409, Fax: +390403785494 
Email: samuele.naviglio@gmail.com 
Contact details of other authors: 
Giorgio Ottaviano: g.ottaviano88@gmail.com 
Silvia Salvatore: silvia.salvatore@uninsubria.it 
Alessandro Salvatoni: alessandro.salvatoni@uninsubria.it 
Stefano Martelossi: stefano.martelossi@aulss2.veneto.it 
Alessandro Ventura: alessandro.ventura@burlo.trieste.it 
 
Short title: Ocular manifestations of pediatric IBD 
Non-standard abbreviations:  O-EIMs: Ocular extraintestinal manifestations 
Downloaded from https://academic.oup.com/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjy029/4922546
by Biblioteca IRCCS Ospedale infantile e Pie Fondazioni Burlo Garofolo e dott. Alessandro ed Aglaia de Manussi user
on 14 March 2018
Ac
ce
pte
d M
an
us
cri
pt
Manuscript Doi: 10.1093/ecco-jcc/jjy029 
 
ABSTRACT 
 
Background and aims: Ocular extraintestinal manifestations (O-EIMs) are known 
complications of Crohn’s disease (CD), ulcerative colitis (UC) and inflammatory bowel 
disease unclassified (IBD-U). However, data on their prevalence in children are scarce and 
there are no clear recommendations on which follow-up should be offered. We aimed to 
review available data on O-EIMs in children. 
Methods: In January 2018, we performed a systematic review of published English literature 
using PubMed and EMBASE databases using disease-specific queries.  
Results: Fifteen studies (7467 patients) reported data on O-EIMs prevalence in children. 
Overall prevalence of O-EIMs was 0.62% - 1.82%. Uveitis was the most common O-EIM. 
Meta-analysis showed that children with CD are at increased risk of O-EIMs as compared 
with children with UC and IBD-U (OR 2.70, 95% CI 1.51-4.83). Five studies (357 patients) 
reported data on ophthalmologic screening in asymptomatic children: mild asymptomatic 
uveitis was identified in a variable proportion of patients (1.06%-23.1%), more frequently in 
male patients with CD and colonic involvement. No evidence of ocular complications from 
untreated uveitis was detected. Twenty-three case reports (24 patients) were identified. 
Conclusions: Data on O-EIMs in children are scarce. Prevalence of O-EIMs is lower than in 
adults but may be underestimated because of the possibility of asymptomatic uveitis; 
however, the long-term significance of this condition is unknown. Children with CD may be 
at increased risk of O-EIMs. No recommendations on routine ophthalmological examination 
can be made but a low threshold for ophthalmologic referral should be maintained. Larger 
studies in pediatric IBD populations are needed. 
Keywords: ocular; extraintestinal manifestations; eye; IBD; children.
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INTRODUCTION 
 
Inflammatory bowel disease (IBD), including Crohn disease (CD), ulcerative colitis (UC), 
and IBD-unclassified type (IBD-U), are chronic inflammatory disorders mainly affecting the 
gastrointestinal tract. They are associated with various extra-intestinal manifestations (EIMs), 
which affect approximately 10% to 40% of patients,
1–3
 and may potentially involve almost 
any organ, even before gastrointestinal symptoms. Ocular EIMs (O-EIMs) have been 
recognized since the early descriptions by Crohn,
4
 and are among the most common EIMs. 
Uveitis and episcleritis are among the most commonly reported conditions in adult patients, 
with a prevalence between 2% and 6% in large cohort studies,
3,5,6
 but when a wider spectrum 
of ocular conditions is considered, a higher prevalence has been reported.
6–9
 O-EIMs may be 
associated with potentially severe outcomes. Uveitis, in particular, is associated with ocular 
pain, photophobia, and blurred vision, and when untreated may lead to several ocular 
complications, including keratopathy, cataract, glaucoma, posterior synechiae, cystoid 
macular edema, and permanent vision loss. Other, rarer but potentially severe ocular 
manifestations in patients with IBD include retinal vasculitis, central retinal artery/vein 
occlusion, retrobulbar neuritis, keratopathy, and orbital myositis.  
Data on O-EIMs prevalence and clinical course in children are scarce and there are no clear 
recommendations on which ophthalmologic investigations and follow-up should be offered, 
unlike other pediatric inflammatory disorders, such as Juvenile Idiopathic Arthritis, for which 
an ophthalmological screening schedule has been developed.
10
 We aimed to review published 
data on the prevalence and clinical course of O-EIMs from observational studies in children 
with IBD, in order to better define their epidemiology and clinical characteristics, as well as 
possibly identifying clinical phenotypes that may be associated with a higher risk of ocular 
involvement. 
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METHODS 
 
We performed a systematic review of O-EIMs in IBD children according to the MOOSE 
guidelines.
11
 Search strategy: We searched PubMed and EMBASE databases for studies 
published from inception to January 31, 2018, using the following queries: [1] (uveitis OR 
scleritis OR episcleritis OR iritis OR iridocyclitis OR "pars planitis" OR choroiditis OR 
chorioretinitis OR retinitis OR papillitis OR ocular OR eye OR ophthalmologic OR 
ophthalmic OR orbital OR retinal OR optic OR dacryoadenitis OR keratopathy OR corneal 
OR conjunctivitis OR blepharitis OR cataract OR intraocular OR "visual acuity" OR 
blindness OR uveal OR lacrimal) AND (Crohn OR "ulcerative colitis" OR "inflammatory 
bowel disease"); [2] ("extraintestinal manifestation" OR "extra-intestinal manifestation" OR 
"extraintestinal manifestations" OR "extra-intestinal manifestations") AND (children OR 
pediatric) AND ("Crohn" or "ulcerative colitis" OR "inflammatory bowel disease").  
 
Data selection: Two authors (GO, SN) independently reviewed search results and found a 
consensus on the articles to be included. Articles references were also considered for 
additional studies. To be analyzed, studies had to report original data on O-EIMs in children 
with IBD.  We included observational studies, as well as case reports. Limits related to age 
(0-18 years) and languages (English) were applied. Abstracts and unpublished studies were 
not included. If studies contained data from both adult and pediatric IBD patients, data from 
the two populations had to be clearly discernible. When articles contained potentially relevant 
data but not fully reported, the authors were contacted by e-mail for further information. Only 
in two cases contacted authors were able to provide the requested information, which were 
therefore included in our review, while the other authors declared the inability to provide 
their complete data.  
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Meta-analysis: Mantel-Haenszel weighting and random effects models were used. Statistical 
heterogeneity across studies was measured using the Cochran chi-square test (p < 0.1 
considered significant) and the I
2
 statistic. Variance was evaluated by means of tau
2
. All 
statistical tests were two sided using an α level of 0.05. Publication bias was assessed by 
funnel plot. The meta-analyses were conducted with the statistical software Review Manager 
(RevMan) version 5.3 (The Cochrane Collaboration, 2014, Copenhagen, Denmark). 
 
RESULTS 
 
We retrieved 1499 and 264 articles from the query one and two, respectively. We excluded 
1470 and 247 articles because they did not meet inclusion criteria. Seven articles were found 
through both queries. Four other articles were found through the reference list of the included 
articles. In conclusion, we selected 43 articles for the analysis (Figure 1). 
 
Prevalence of O-EIMs in children: Fifteen studies, including a total of 7467 patients, reported 
the prevalence of symptomatic ocular complications in children (table 1).
12–24
 Substantial 
heterogeneity was present among studies. Timing of data collection varied, as some studies 
included only O-EIMs present at IBD diagnosis while others also considered O-EIMs 
appearing during follow-up. Studies also differed for O-EIMs inclusion criteria, since some 
authors reported data only for uveitis, while others also included other O-EIMs (e.g. 
episcleritis, papilledema, corneal infiltrates), and other articles generically reported “ocular 
manifestations”, without further details. Finally, the modality of O-EIMs ascertainment was 
poorly described or not reported in most studies, making comparative evaluation difficult to 
perform. 
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Overall prevalence of O-EIMs in IBD at diagnosis ranged from 0.62% (3/483 patients, 
Dimakou et al.) to 1.81% (1/55 patients, Abdul Aziz et al.). Prevalence during follow-up 
ranged from 0.69% (7/1009 patients, Dotson et al.) to 1.82% (6/329 patients, Greuter et al.). 
The largest available study (Jose et al.) reported data about the first EIM in a cohort of 1649 
North-American children with IBD. Among 387 children with a first EIM, 7% (27/387) had 
an O-EIM; 52 and 13 out of 387 children developed also a second and a third one, 
respectively, yet data on these EIMs were not detailed and when contacted authors could not 
provide further information; however, an overall incidence rate for anterior uveitis of 0.18 per 
100 patient-years was reported. This study was also the only one among larger studies that 
analyzed the prevalence of different types of O-EIMs, with uveitis being the most commonly 
reported condition (17 patients out of 27 with O-EIMs), followed by papilledema and corneal 
infiltrates (7 patients – aggregate data). 
A trend towards greater prevalence of O-EIMs in children with CD emerged from several 
studies yet this difference did not reach statistical significance, possibly because of the 
limited number of patients included in each study. We performed a meta-analysis to assess 
the risk of O-EIMs in children according to the different IBD diagnosis. We compared the 
prevalence of O-EIMs in children with CD versus children with UC and IBD-U; these two 
latter groups of patients were analyzed together because not all the studies differentiated 
between them. Only studies including both categories of patients were included in the meta-
analysis to allow direct between groups comparison. Children with CD were found to be at 
increased risk of O-EIMs (odds ratio 2.70, 95% CI 1.51-4.83, p = 0.0008) (Figure 2). No 
significant heterogeneity was detected among studies as evaluated by Cochran’s chi squared 
(p = 0.96) and I
2
 statistic (I
2
 = 0%); nevertheless data on O-EIMs diagnosis criteria and 
patients’ characteristics for each study were scarce or absent. Publication bias did not seem to 
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be relevant as evaluated by funnel plot (data not shown), yet the number of available studies 
was low. 
Dotson et al. evaluated the association of O-EIMs with intestinal disease localization, 
presence of perianal disease, patient’s age and sex, but no significant association was found. 
One study (Gower-Rousseau et al.) reported a remarkably high prevalence of uveitis during 
follow-up in children with UC (4 of 113 patients, 3.54%). However, this study was relatively 
small and was performed only in patients with UC. Greuter et al. also included data on timing 
of uveitis appearance in their population: 6 of 329 patients in their cohort had a diagnosis of 
uveitis, which occurred at a median time of approximately 7 years after IBD diagnosis, with 
one case preceding intestinal disease onset.
17
 The same study group published also a separate 
sub-analysis of patients from the same database (the Swiss IBD Cohort Study) evaluated at 
10 years (range 108-132 months) of follow-up.
25
 After 10 years, age at IBD diagnosis did not 
appear to influence risk of uveitis, with similar incidence rates in patients with IBD diagnosis 
<10 years of age, <17 years of age, <40 years of age, and  >40 years of age.  
No study did provide information about the prevalence of O-EIMs according to the patients’ 
ethnicity. Jose et al. included data on patients’ ethnicity, reporting no difference on the 
overall risk of EIMs, but no information was available for O-EIMs.
12
 Finally, few studies 
provided details about concurrent treatments: Dotson et al. observed a protective effect of 
treatment mesalamine/sulfasalazine, infliximab, and immunomodulators on the overall risk 
EIMs for patients with moderate to severe disease as compared to patients who had not 
received these treatments; no data, however, were specifically available for O-EIMs.
15
 
Finally, Greuter et al. reported the effect of treatment with anti-TNF on uveitis: 2 patients out 
of 3 experienced uveitis improvement with treatment; however, in 2 patients uveitis appeared 
during anti-TNF treatment.   
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Screening for O-EIMs in children: Five studies (including 357 patients) reported data on 
small cohorts of asymptomatic children who underwent ophthalmological screening 
regardless of the presence of ocular symptoms.
22,26–29
 Four studies (including 299 patients) 
included full ophthalmologic evaluation (table 2), while a fifth study (Tripathi et al.) 
evaluated only ocular side effects of corticosteroid treatment.  
Studies reporting full ophthalmologic evaluation found asymptomatic uveitis (i.e. subclinical 
uveitis detected only by slit-lamp examination) in several children with IBD. Three studies 
(Daum et al., 1979; Hofley et al. 1993; Rychwalski et al., 1997) reported a prevalence of 
asymptomatic uveitis substantially higher than prevalence of O-EIMs from cohort studies: 
4.1% (6/147 patients, Hofley et al.), 12.5% (4/32 patients, Rychwalski et al.), and 23.1% 
(6/26 patients, Daum et al.). More recently, Naviglio et al. reported a lower prevalence (1/94 
patients, 1.06%) of uveitis in a sample of pediatric patients with IBD who had undergone 
ophthalmologic screening evaluation. In this study, only one patient was found to have 
asymptomatic anterior uveitis on screening slit lamp examination; the same patient also had a 
history of previous bilateral symptomatic (i.e. eye redness and discomfort) anterior uveitis 7 
years before, at IBD onset. Uveitis had been treated with dexamethasone eye drops and had 
not recurred after. No other patient had a history of O-EIMs diagnoses. Furthermore, no 
patient had ocular signs of complications from previous, unrecognized uveitis at 
ophthalmologic evaluation.  
Considering combined data from these four studies, a total of 299 patients were screened 
(180 CD, 117 UC, and 2 IBD-U). Asymptomatic uveitis was detected in 18/299 patients 
(4.86%) and was characterized as mild anterior uveitis in all patients. Asymptomatic uveitis 
was detected more frequently in CD (CD/UC = 17/1; prevalence in CD patients = 9.4%; 
prevalence in UC patients = 0.85%), adolescent (mean age 14.5 years), and male (M/F = 
14/4) patients. Colonic involvement was prevalent (13 out of 14 patients for which data are 
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available). Presence of HLA-B27 was reported only by Daum et al. (1/6 patients). Intestinal 
disease activity was not related to ocular inflammation (active intestinal disease in 6/12 
patients with uveitis; no data available from Daum et al.). In all cases of asymptomatic uveitis 
no specific treatment was deemed necessary. Data on short-term follow-up (4-12 months) are 
available only for patients reported by Daum et al and Naviglio et al.: uveitis resolved in 6/7 
patients overall (1 patient was lost to follow-up); the long-term outcomes were not reported. 
Posterior subcapsular cataract, a known adverse effect of corticosteroid treatment, was 
detected in 6 patients (5 by Rychwalski et al. and one by Naviglio et al.), and in no patients 
from the other two studies (overall prevalence 6/299 patients, 2.0%).  
A fifth study, by Tripathi et al., performed an ophthalmologic evaluation targeted at ocular 
side effects of corticosteroid treatment.
29
 Fifty-eight pediatric patients with IBD treated with 
corticosteroids as well as 58 age-matched controls were evaluated. Most patients (38/58) had 
received corticosteroid treatment for more than a year (range 1-104 months). Posterior 
subcapsular cataract was detected in 12 patients (20.7%) and in none of the controls. Patients 
also had a significantly higher intraocular pressure (15.89 +/- 4.11 mmHg vs. 13.63 +/- 2.35 
mmHg, p <0.001), with 21 patients (36.2%) defined as “intraocular pressure responders" 
(intraocular pressure ≥20 mmHg, or change ≥ 6 mmHg between visits, or a difference ≥6 
mmHg between the two eyes). Overall 30 patients (52%) had either cataract or abnormal 
intraocular pressure. Cataract risk was not correlated with the total dose of corticosteroids, 
duration of treatment, average daily dose or number of days on higher doses, while increased 
intraocular pressure was correlated with average daily dose in the last 30 days. At follow-up 
visits, performed at 3-18 months after initial evaluation, dose-related changes in 
ophthalmologic findings were observed. Notably, cataract regression was observed in two 
patients lowering the prednisone daily dose to less than 10 mg/day of prednisone. Similarly, 
increased ocular pressure responded to lowering of dose to less than 10 mg/day; on the other 
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hand, an increase in corticosteroid dose was associated with abnormal intraocular pressure in 
some patients with previously normal findings. 
 
Case reports: we retrieved 23 case reports/case series including 24 children with O-EIMs 
(table 3). Reported conditions included: central retinal vein/artery occlusion,
30–32
 orbital 
myositis/orbital pseudotumor,
33–39
 choroidal neovascular membrane,
40
 nasolacrimal duct 
obstruction,
41
 dacryoadenitis,
42
 dry eyes syndrome,
43
 cataract,
43
 unilateral/bilateral uveitis,
44–
46
 episcleritis,
47
 keratopathy/keratitis,
48,49
 granulomatous conjunctivitis,
50
 optic neuritis,
51
 and 
recurrent neuroretinitis.
52
 All patients presented with ocular symptoms when evaluated, 
including reduced visual acuity (even sudden vision loss), ocular pain/discomfort, redness, 
eyelid swelling, proptosis, photophobia, and diplopia. Considering all patients for which 
detailed information were available, more patients were males (M/F = 14/8) and had CD 
(CD/UC = 18/5). Mean age at O-EIM onset was 13 years (range 2-20 years). Five patients 
were diagnosed with ophthalmological conditions before IBD onset, while in 11 patients they 
were present at IBD diagnosis. When O-EIMs occurred after IBD onset, latency ranged from 
2 to 8 years. Complete resolution was reported in most cases of inflammatory complications 
(i.e. uveitis, orbital myositis/pseudotumor, neuroretinitis, and optic neuritis), yet persistent 
visual impairment was reported in a 6-year-old boy with intermediate uveitis who had 
residual amblyopia despite resolution of uveitis.
46
 Treatment included systemic steroids in 
almost all reported cases; methotrexate was used in one case of orbital pseudotumor, leading 
to resolution.
39
 Vascular conditions (central retinal artery or vein occlusion, choroidal 
neovascular membrane) had a worse prognosis, with residual visual impairment in 3 out of 4 
patients.    
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DISCUSSION 
 
Data on ocular involvement in children with IBD are scarce and fragmented. Substantial 
heterogeneity among studies and several methodological issues currently limit the complete 
evaluation of this topic. Among cohort studies reporting prevalence of O-EIMs in children 
with IBD, inclusion criteria for O-EIMs were, in fact, highly variable, with some authors 
focusing only on selected conditions (e.g. uveitis) and others reporting the presence of 
“ocular manifestations” without further specification. Furthermore, criteria for the diagnosis 
of O-EIMs are not fully defined in most studies. Notwithstanding these limitations, data from 
cohort studies indicate a lower prevalence of ocular involvement in children (0.6-1.8%) than 
in adults (2-6%). Data on different types of O-EIMs are even scarcer, with only one report 
(Jose et al. 2009) showing different prevalence for selected ocular conditions (uveitis, 
papilledema, corneal infiltrates). According to this study, uveitis represents the most common 
O-EIM in children with IBD. Subtype and localization of uveitis were not indicated, yet in 
adult patients anterior uveitis (i.e. iritis/iridocyclitis) is predominant.
53 Data on prevalence of 
other O-EIMs such as episcleritis/scleritis or rarer conditions such as orbital myositis are not 
available, and only data from case reports are presented. 
O-EIMs can affect both CD and UC patients, yet our meta-analysis showed that children with 
CD are at increased risk of O-EIMs as compared to other pediatric IBD, with an odds ratio of 
2.70. No significant study heterogeneity was detected, yet, given the paucity of information 
available, we had to consider together in the analysis studies on EIMs at diagnosis and during 
the follow-up. Nevertheless, the evaluated outcome (prevalence of O-EIMs) was uniform, 
and there are no data from both pediatric and adult studies suggesting that timing of data 
collection timing may bias prevalence among different IBD subtypes (CD vs. UC vs. IBD-
U). Hence we can assume that including both types of studies (at diagnosis vs. during follow 
Downloaded from https://academic.oup.com/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjy029/4922546
by Biblioteca IRCCS Ospedale infantile e Pie Fondazioni Burlo Garofolo e dott. Alessandro ed Aglaia de Manussi user
on 14 March 2018
Ac
ce
pte
d M
an
us
cri
pt
Manuscript Doi: 10.1093/ecco-jcc/jjy029 
 
up) did not affect the relative risk analysis. In adult patients, O-EIMs are often considered to 
be more frequent in CD as compared to UC;
54
 however, data from studies on adult patients 
are conflicting, with only some studies reporting a significantly increased prevalence of O-
EIMs in CD patients, while in others the difference appears to be nonsignificant.
1,3,55,56
  
Data on timing of O-EIMs in children are also scarce. Greuter et al. reported a median time of 
7 years after IBD diagnosis for uveitis onset, although substantial variability was observed. 
Occurrence of O-EIMs before gastrointestinal symptoms onset is also possible, even though 
in a minority of patients; O-EIMs that have been reported to precede intestinal disease 
include uveitis and orbital myositis. Results from the largest study (Jose et al., 2009) indicate 
that the prevalence of uveitis increases with time (incidence rate: 0.18 cases per 100 patient-
years). Herzog et al. reported no difference for uveitis rates according to age at IBD diagnosis 
when patients were evaluated after 10 years, possibly indicating that age at IBD onset does 
not influence uveitis risk per se. 
Very little data are available also for correlation of O-EIMs with intestinal disease activity. 
While uveitis is classically considered to be unrelated to intestinal disease activity, some 
studies on adult patients actually found a significant correlation with disease activity in 
patients with CD (but not in UC).
1
 Few studies specified concurrent treatments in IBD 
patients, which may possibly have an effect on the risk of O-EIMs during follow-up. Dotson 
et al reported a protective effect of immunomodulators and anti-TNF on the overall risk of 
EIMs in their cohort, yet no data were available for O-EIMs. While systemic 
immunomodulatory treatments could possibly reduce the risk of inflammatory O-EIMs, this 
relationship may not be straightforward. In fact, Greuter et al reported a good response of 
uveitis to anti-TNF antibodies in 2 out of 3 patients, yet the same Authors detected uveitis 
during anti-TNF treatment in other two patients.  
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We did not find evidence of a difference in prevalence of O-EIMs according to patients’ 
ethnicity. No study provided information on patients’ ethnicity as related to O-EIMs, yet 
among prevalence studies several world regions were actually included (North America, 
Western Europe, Turkey, Saudi Arabia, South Korea) and no difference in overall prevalence 
was observed. Jose et al. reported no significant association for patients’ ethnicity with 
overall EIMs prevalence, but no specific data were available for O-EIMS. Another study, by 
Eidelwein et al., compared EIMs prevalence between white and African American children in 
North America.
57
 This study, however, could not be included in the prevalence analysis 
because it did not show exact figures of the condition, stating only that uveitis prevalence 
was “less than 3%” in both groups of patients. Contacted authors also could not provide 
further information. Nonetheless, no difference in overall EIMs prevalence was reported. 
Similarly, White et al. found no difference in overall EIMs prevalence in African American 
children with IBD as compared to other ethnic groups; however, sub-analysis of different 
types of EIMs was not performed, nor could contacted authors provide further information.
58
 
Remarkably, data from adult patients seem to suggest that prevalence of uveitis may be 
higher in African American CD patients as compared to other ethnic groups.
59–61
 
The recognition of subclinical uveitis by slit-lamp examination in screening evaluation in 
small samples of asymptomatic children with IBD raises concerns about under-diagnosis of a 
potentially invalidating condition. Three studies (Daum et al., 1979; Hofley et al. 1993; 
Rychwalski et al. 1997) showed a significantly increased prevalence of subclinical uveitis 
(4.1% - 23.1%) compared to that reported in cohort populations. It may be worth noting that 
these studies were performed more than 20 years ago (between 1979 and 1997), before the 
introduction of biologic anti-tumor necrosis factor alpha agents and the wider use of immune 
modulators, which allowed a better control of both gastrointestinal manifestations and 
EIMs.
62,63
 The more recent report by Naviglio et al., while confirming the existence of 
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subclinical uveitis in children with IBD, indicated a lower prevalence (1.06%), in line with 
the prevalence from cohort studies. In all these studies, asymptomatic uveitis was anterior, 
confirming this as the most common type of uveitis associated with IBD in children, even 
though other types of uveitis (e.g. intermediate uveitis) are also possible.
46
 Asymptomatic 
uveitis did not seem to correlate with intestinal disease activity. Interestingly, some clinical 
characteristics recurred among patients with asymptomatic uveitis: they were more 
commonly adolescent males with CD and with colonic involvement (13/14 patients). This 
may confirm CD patients are at increased risk of O-EIMs. Recent data have suggested that 
eye-specific autoreactive T cells may be activated in the gut from an antigen dependent cross-
reaction on commensal microbiota.
64
 Abnormal gut permeability in CD and increased density 
of microbiota in the colon could explain the increased risk of O-EIMs in these patients. 
However, the low number of cases does not allow to draw a general conclusion nor to 
identify other significant characteristics.  
Clinical implications of asymptomatic uveitis are unclear. In fact, most cases were diagnosed 
as mild uveitis, and both Daum et al. and Naviglio et al. reported spontaneous resolution of 
ocular inflammation without specific treatments, suggesting asymptomatic uveitis in children 
with IBD may be transient and self-limiting. Remarkably, no studies detected evidence of 
ocular complications from previous unrecognized uveitis, suggesting this type of ocular 
manifestation may not be aggressive or lead to complications, at least in children with IBD. 
This is in sharp contrast with asymptomatic uveitis associated with other pediatric chronic 
inflammatory disorders, such as juvenile idiopathic arthritis-associated uveitis, which has a 
high potential for ocular complications and visual impairment.
65
 Nevertheless, natural history 
of asymptomatic uveitis in IBD is poorly known, therefore definitive conclusions cannot be 
drawn. Notably, several treatments used in IBD are also effective for uveitis, therefore uveitis 
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may also benefit from systemic treatments used to control intestinal disease. New studies are 
needed to outline specific phenotype risk and orientate proper follow-up for these patients.  
Iatrogenic ocular complications, mainly corticosteroid-induced posterior subcapsular cataract 
and increase of intraocular pressure, should also always be considered in children with IBD 
receiving corticosteroids. Available data on this complication come mostly from the case-
control study by Tripathi et al. The majority of children (52%) developed either cataract or 
alteration of intraocular pressure; however, this study was performed mainly on children 
receiving long-term corticosteroid treatment, an eventuality that has now become less 
frequent, as corticosteroids are considered more as a “bridge therapy”. There are few data in 
medical literature defining timing and dose-related risk of corticosteroid-induced ocular 
complications in children. It is now well recognized that there is a high inter-individual 
variability in sensitivity to ocular adverse effects of corticosteroids, with some patients free 
of ocular complications after years of corticosteroid treatment, while in others they may 
develop rapidly (even as soon as after two weeks of treatment).
66
 Data from adult patients 
seem to indicate that the overall risk is dose- and time-related, even though a “safe dose” 
does not seem to exist.
67
 Notably, corticosteroid-induced complications, especially increased 
intraocular pressure, did respond to dose lowering to less than 10 mg/day of prednisone in the 
study by Tripathi et al., yet we have not enough data to consider this as a “safe” dose. 
Therefore, at present, a precise threshold for corticosteroid dose or treatment duration to 
guide ophthalmological evaluation cannot be clearly defined. In the study by Tripathi et al. 
the risk of cataract was not correlated to treatment duration or steroid dose, while the risk of 
abnormal intraocular pressure was associated to the average dose in the previous 30 days. It 
may be possible therefore to consider that this is an adequate timing for alterations of 
intraocular pressure to develop, therefore, it could be reasonable to suggest that in children in 
whom systemic corticosteroid are considered for longer periods of time and not as a “bridge 
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therapy” (i.e. in whom tapering and suspension are not programmed after one month) an 
ophthalmologic evaluation, including intraocular pressure measurement, should be 
considered after one month of therapy. Timing for subsequent evaluations should be decided 
by the referral ophthalmologist, as there are no data to guide patient management. It is 
noteworthy that in the study by Tripathi et al. some patients with a previously normal 
ophthalmologic evaluation developed complications after a significant increase in their daily 
corticosteroid dose, therefore this should also be taken in consideration in guiding follow-up. 
All these recommendations are based on low/moderate quality evidence (one case-control 
study), and therefore their strength should be considered as weak. Patients on very long-term 
corticosteroid treatment (i.e. continuative treatment for several months/years), however, are 
at high risk of ocular complications and a strict ocular follow-up should be offered. 
Available case reports of O-EIMs define a wide array of ocular conditions that have been 
reported in children with IBD. However, for some of them it is currently not possible to 
determine whether they were simply coincidental, though similar manifestations have been 
reported in adult patients. Presenting symptoms varied widely, from mild ocular redness or 
discomfort to complete loss of visions, highlighting the need not to underestimate ocular 
complaints in these patients. Reported O-EIMs can be roughly classified in inflammatory and 
vascular conditions. The first group includes uveitis, episcleritis, orbital 
myositis/pseudotumor, dacryoadenitis, and optic neuritis. Orbital pseudotumor, which 
identifies any inflammatory enlargement of intraorbital structures elements,
68
 despite being a 
rare condition, was one of the most commonly reported O-EIMs in case reports. While the 
clinical manifestations may vary widely depending on the structures affected, they often 
included ocular/orbital pain, diplopia, ophthalmoplegia, proptosis, eyelid swelling, and 
reduced visual acuity. Almost all cases involving an inflammatory O-EIM resolved with 
treatment, which usually included systemic corticosteroids.  
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Among vascular conditions we identified reports on both retinal artery or vein occlusion, and 
choroidal neovascular membrane; these complications may also share an inflammatory 
pathogenesis, possibly due to retinal vasculitis, which has been associated with IBD in 
adults.
69
 In most cases, vascular conditions resulted in some residual visual impairment 
despite treatment. Notably, also among case reports there was a preponderance of children 
with CD (CD/UC = 18/5), thus possibly confirming a greater incidence of O-EIMs in CD 
patients.  
In conclusion, available data indicate that prevalence of O-EIMs in children is lower than in 
adult patients, yet children with CD seem to be at increased risk as compared to other groups 
of patients. Prevalence of O-EIMs in children may be underestimated in consideration of the 
possibility of asymptomatic uveitis, which has not been described in adults.
70
 The 
significance of this condition, however, is unclear, as all reported cases were mild and self-
limiting, with no evidence of ocular complications from underdiagnosis. Nevertheless, data 
on natural history of this manifestation and long-term follow-up are lacking. It has been 
recently suggested that annual screening eye examination should be considered in all children 
with IBD;
71
 however, this is often not performed in clinical practice, nor it is possible to 
define the cost-benefit ratio of such an approach. Currently, the paucity of data on O-EIMs in 
children does not allow to draw clear conclusions on which ophthalmologic follow-up should 
be provided. An option may be to perform ophthalmologic evaluation at IBD diagnosis in 
order to have a baseline reference, yet we cannot provide any evidence for this suggestion. 
On the other hand, we recommend that a low threshold for ophthalmologic referral should be 
maintained in all children with IBD, both at the diagnosis and during follow-up. Available 
data, in fact, show that most children with O-EIMs presented some ocular signs or symptoms, 
therefore ocular complaints should never be dismissed, and both health care providers and 
patients/care givers be instructed about the increased risk of ocular complications in children 
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with IBD. Since available data indicate a higher incidence of O-EIMs in children with CD, 
especially if colonic involvement is present, this subset of patients may be considered at 
higher risk of O-EIMs in clinical practice, but further studies on larger groups of patients are 
needed. Finally, patients receiving systemic corticosteroids for more than brief periods may 
probably benefit from ophthalmologic evaluations, including intraocular pressure 
measurement. A strict follow-up should be offered in patients receiving long-term 
corticosteroid treatment, as these children are at increased risk for iatrogenic ocular 
complications. 
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Table 1: Studies reporting prevalence of O-EIMs in IBD children (ordered by 
population size) 
 N. of 
IBD 
patients 
O-EIMs 
considered 
Timing of data 
collection 
O-EIMs 
prevalence 
O-EIMs prevalence 
according to IBD type 
 CD UC IBD-U 
Jose et al.  
(2009) 
1649 Uveitis, 
Papilledema, 
Corneal 
infiltrates 
During follow-
up 
(only first-
appearing 
EIMs) 
1.63% 
(27/1649) 
 
- - - 
Card et al. 
(2016) 
1594 Uveitis During follow-
up 
1.63%  
(26/1594) 
2.07% 
(21/1014) 
0.86% 
(5/580) 
- 
 
Castro et al. 
(2008) 
1576 Ocular 
manifestations, 
not better 
specified 
At diagnosis 1.07% 
(17/1576) 
1.73% 
(11/635) 
0.74% 
(6/810) 
0% 
(0/131) 
Dotson et al. 
(2010) 
1009 Uveitis During follow-
up 
0.69% 
(7/1009) 
0.82% 
(6/728) 
0.36% 
(1/281) 
- 
Dimakou et al. 
(2015) 
483 Ocular 
manifestations, 
not better 
specified 
At diagnosis 0.62% 
(3/483) 
0.60% 
(1/167) 
0.37% 
(1/267) 
2.04% 
(1/49) 
Greuter et al. 
(2017) 
329 Uveitis During follow-
up 
1.82% 
(6/329) 
2.9% 
(5/173) 
0.64% 
(1/156)* 
Duricova et al. 
(2017) 
158 Uveitis At diagnosis 1.27% 
(2/158) 
- 1.27% 
(2/158) 
- 
Cakir et al. 
(2015) 
127 Uveitis At diagnosis 1.57% 
(2/127) 
3.4% 
(1/29) 
1.1% 
(1/90) 
- 
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Gower-
Rousseau et al. 
(2009) 
113 Uveitis During follow-
up 
3.54% 
(4/113) 
- 3.54% 
(4/113) 
- 
Martinelli et al. 
(2017) 
111 Uveitis During follow-
up 
1.80% 
(2/111) 
- 1.80% 
(2/111) 
- 
Saadah  
(2012) 
96 Uveitis, Keratitis At diagnosis 2.11% 
(2/96) 
2.11% 
(2/96) 
- - 
Naviglio et al. 
(2017) 
94 Uveitis During follow-
up 
1.06% 
(1/94) 
2.17% 
(1/46) 
0% 
(0/46) 
0% 
(0/2) 
Lee et al. 
(2016) 
73 Uveitis During follow-
up 
1.37% 
(1/73) 
1.37% 
(1/73) 
- - 
Abdul Aziz 
(2017) 
55 Uveitis At diagnosis 1.81% 
(1/55) 
10% 
(1/10) 
0% 
(0/34) 
0% 
(0/11) 
 
* aggregate data (UC+IBD-U) 
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Table 2: Studies reporting full ophthalmological screening in children with IBD 
 N. patients 
 
 
Asymptomatic uveitis  Cataract 
Overall CD UC 
Daum et al. (1979) 26 23.08% 
(6/26) 
31.58% 
(6/19) 
0% 
(0/7) 
0% 
Hofley et al. (1993) 147 4.08% 
(6/147) 
6.19% 
(6/97) 
0% 
(0/50) 
0% 
Rychwalski et al. (1997) 32 12.50% 
(4/32) 
16.67% 
(3/18) 
7.14% 
(1/14) 
15.63% 
(5/32) 
Naviglio et al. (2017) 94 1.06% 
(1/94) 
2.17% 
(1/46) 
0% 
(0/46) 
1.06% 
(1/94) 
Total 299 4.86% 
(18/299) 
9.44% 
(17/180) 
0.85% 
(1/117) 
2.00% 
(6/299) 
 
Downloaded from https://academic.oup.com/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjy029/4922546
by Biblioteca IRCCS Ospedale infantile e Pie Fondazioni Burlo Garofolo e dott. Alessandro ed Aglaia de Manussi user
on 14 March 2018
Ac
ce
pte
d M
an
us
cri
pt
Manuscript Doi: 10.1093/ecco-jcc/jjy029 
 
Table 3: Case reports on ocular complications in children with IBD 
1st author,  
Year 
Ocular signs 
and 
symptoms 
O-EIM 
diagnosis 
IBD O-
EIM 
onset 
(y) 
IBD 
onset 
(y) 
Sex IBD 
localization 
Other EIMs Therapy Outcome 
Symeonidis 
(2017) 
Low visual 
acuity 
Unilateral 
intermediate 
uveitis 
CD 6 6 (after 
5 
months)  
M Terminal 
ileum 
Arthritis  Systemic 
steroids 
Resolved 
uveitis, 
persistent 
amblyopia 
Lapsia (2016) Low visual 
acuity  
Bilateral 
central retinal 
vein occlusion 
UC 19 17 M ND ND Enoxaparin 
Bevacizumab 
Colectomy 
Improved 
visual acuity 
Vargason 
(2015) 
Eyelid 
swelling 
Orbital 
myositis 
CD 15 15 M Terminal 
ileum 
ND Systemic 
steroids 
Methotrexate 
Resolved 
Tan (2014) Ocular pain 
and swelling 
Bilateral 
orbital 
pseudotumor 
UC 2 2 F Pancolitis Arthritis 
Vasculitis 
NSAIDs Resolved 
Thomas 
(2014) 
Low visual 
acuity 
Unilateral 
choroidal 
neovascular 
membrane 
CD 13 15 M ND ND Intravitreal 
bevacizumab 
Stabilized 
Fasci-Spurio 
(2014) 
Low visual 
acuity 
 
Bilateral 
rosacea-like 
keratopathy  
CD 16 16 M Pancolitis EN 
Acne rosacea 
Anti-TNF 
discontinuation 
Resolved 
Falavarjani 
(2012) 
Low visual 
acuity 
 
Unilateral 
central retinal 
artery 
occlusion 
CD 9 5 M ND ND None Optic nerve 
atrophy 
Greninger 
(2012) 
Epiphora 
Enlarged 
lacrimal sacs 
Bilateral 
granulomatous 
dacryocystitis 
CD 16 13 M Ileocolonic Granulomatous 
cheilitis 
External 
dacryocysto-
rhinostomy 
ND 
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Barabino 
(2011) 
Bilateral 
visual loss 
 
Optic neuritis CD 11 11 M Stomach, 
duodenum, 
colon 
ND Systemic 
steroids 
Resolved 
Paroli (2011) Bilateral 
ocular pain 
redness 
Bilateral 
anterior 
uveitis, optic 
disc edema 
CD 4 12 M ND EN, Arthritis  
Aphthous 
stomatitis 
Topical and 
systemic 
steroids 
Resolved 
Vayalambrone 
(2011) 
Low visual 
acuity 
Nonischemic 
central retinal 
vein occlusion 
UC 16 16 F ND ND ND Improved 
visual acuity 
Girardin 
(2007) 
Low visual 
acuity 
Photophobia 
Bilateral 
anterior uveitis 
CD 17 17 M Stomach, 
duodenum, 
ileocolonic 
ND Topical 
steroids 
Resolved 
Rafiei (2006) Bilateral 
upper eyelid 
swelling 
Bilateral 
dacryoadenitis 
CD 10 10 F Ileum, 
colon 
Arthralgia, 
Aphthous 
stomatitis 
Systemic 
steroids 
Resolved 
Mrugacz 
(2005) 
Low visual 
acuity, 
ocular pain, 
redness, 
photophobia, 
foreign body 
sensation 
Dry eyes, 
bilateral 
posterior 
subcapsular 
cataract 
CD 11 4 F ND ND Hyaluronan 
eye drops 
(tears 
substitute) 
Dry eye 
syndrome 
resolved; 
stable cataract 
Shoari (2005) Low visual 
acuity, 
Ocular pain 
Recurrent 
neuroretinitis 
UC 14 17 M Pancolitis ND Systemic 
steroids 
Improved 
visual acuity 
Read (1999) ND Episcleritis ND 16 ND M ND ND ND ND 
Durno (1997) Proptosis, 
Periorbital 
swelling 
Orbital 
myositis 
CD 12 13 F Stomach, 
duodenum 
ileocolonic 
ND 5-ASA Resolved 
Squires 
(1992) 
Orbital pain  
Diplopia 
Unilateral 
orbital 
myositis 
CD 20 12 M Ileocolonic ND Systemic 
steroids 
Resolved 
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Seo (1992) ND Keratitis CD ND ND ND ND ND ND ND 
ND Chronic 
conjunctivitis 
UC ND ND ND ND ND ND ND 
Blase (1984) Bilateral eye 
redness  
Granulomatous 
conjunctivitis 
CD 13 13 M Rectum ND Systemic 
steroids 
Resolved 
Weinstein 
(1984) 
Ocular pain, 
Diplopia, 
Ptosis 
Unilateral 
orbital 
pseudotumor 
CD 17 17 F Colon ND Systemic 
steroids 
Resolved 
Camfield 
(1982) 
Ocular pain, 
Photophobia 
Bilateral 
orbital 
pseudotumor 
CD 15 15 F Terminal 
ileum 
ND Systemic 
steroids 
Resolved 
Young (1981) Ocular pain, 
Proptosis, 
Diplopia 
Bilateral 
orbital 
pseudotumor 
CD 14 14 F Terminal 
ileum 
ND Systemic 
steroids, 
Bowel 
resection 
Resolved 
 
  ND: no data; NSAID: non-steroid anti-inflammatory drug; EN: erythema nodosum; 5-ASA: mesalamine
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Figure legends 
 
Figure 1 
Flow chart of systematic literature search and selection process for systematic review  
 
Figure 2 
Forest plot for prevalence of O-EIMs among children with IBD 
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Figure 1 
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Figure 2 
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